reports
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB maiden bought 3,843 shares at 39.160USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Minutes from Extraordinary General Meeting
Minutes from Extraordinary General Meeting An extraordinary general meeting of PCI Biotech Holding ASA (“the Company”) took place today, 16 March 2026. All the matters on the agenda were approved in accordance with the proposals set out in the meeting notice, including the proposal to liquidate the Company and to apply for a delisting of the Company’s shares from Euronext Oslo Børs. Liquidation of the Company is expected to occur during first half of 2026. Minutes of the meeting are attached to this release and are available on Contact information: PCI Biotech Holding ASA (unde...
Lifco AB: 1 director
A director at Lifco AB bought 4,000 shares at 306.600SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Notice of Extraordinary General Meeting, proposed company dissolution ...
Notice of Extraordinary General Meeting, proposed company dissolution and delisting Oslo, Norway 23 February 2026 – An extraordinary general meeting of PCI Biotech Holding ASA (‘PCI Biotech’ or ‘Company’) will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 16 March 2026 at 10:00am (CET). The proposed resolutions include company dissolution and delisting from Euronext Oslo Børs. The Board of Directors’ proposed resolution to dissolve PCI Biotech is made as there is no longer any operational activity in the Company, nor is it expected that it will resume such acti...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech initiates a process to evaluate the opportunity for a stru...
PCI Biotech initiates a process to evaluate the opportunity for a structured wind-up process Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic alternatives. This evaluation has now been concluded. Following careful consideration of the PCI Biotech group’s circumstances, the Board has resolved to initiate a process to evaluate the opportunity for a structured wind-up. The liquidity position of the PCI Biotech group remains critical, casti...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech announces discontinuation of R&D operations and continues ...
PCI Biotech announces discontinuation of R&D operations and continues evaluation of future options Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company’s latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued. In recent months, various strategic alternatives have been explored, and this process continues. The evalu...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
PCI Biotech update
PCI Biotech update Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations. Reference is made to the company’s announcements dated 18th August 2025 and 25th September 2025, as well as the interim report for the first half of 2025 published on 29th August 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms. The company’s limited operations and the group’s future...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech update on future operations
PCI Biotech update on future operations Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the discontinuation of further development of the PCL technology. The decision was based on insufficient progress, which extended project timelines and increased resource requirements, elevating the overall project risk to an unacceptable level. Consequently, PCI Biotech decided to discontinue further development. PCI Biotech's immediate priority ha...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
PCI Biotech half-year interim 2025 report
PCI Biotech half-year interim 2025 report Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical ris...
PCI Biotech: Invitation to first half 2025 results presentation and co...
PCI Biotech: Invitation to first half 2025 results presentation and corporate update Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time). The presentation will be held in Norwegian as a live webcast available through There will be a Q&A session at the end of the presentation. Please submit questions to prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.